Goldman Sachs’s Kalaris Therapeutics KLRS Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRS
SL
Goldman Sachs's KLRS Position: Q3 2026 in Review
Goldman Sachs increased its Kalaris Therapeutics (KLRS) stake by 147% in Q3 2026, buying an estimated $91.1K and bringing the position to 39,616 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #6324.
Goldman Sachs first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $6.56M in Q1 2021. 54 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.
- Goldman Sachs held 39,616 shares of Kalaris Therapeutics worth $114K as of Q3 2026.
- Goldman Sachs bought 23,562 Kalaris Therapeutics shares in Q3 2026, an estimated $91.1K.
- Kalaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #6324 holding.
- Goldman Sachs first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
- Goldman Sachs's Kalaris Therapeutics position peaked at $6.56M in Q1 2021.
- 54 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.